Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2009/043068external-prioritypatent/WO2009140127A2/en
Application filed by Boehringer Ingelheim IntfiledCriticalBoehringer Ingelheim Int
Publication of TN2010000521A1publicationCriticalpatent/TN2010000521A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
The present invention relates to an improved process for the preparation of dihydrothienol [3,2-α] pyrimidine diols, and similar pyrimidine diols, that is efficient, high-yielding, and does not require expensive and potentially unstable intermediates.The diols are used as intermediates in the synthesis of pyrimidine compounds which inhibit PDE4 , and are thus useful in the treatment of respiratory or gastrointestinal diseases and complaints , peripheral or central nervous system diseases and disorders, inflammatory conditions , and cancers.
TNP2010000521A2009-05-072010-11-09Synthesis of dihydrothieno [3,2-d] pyrimidine diols and similar pyrimidine diols
TN2010000521A1
(en)
N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2, 3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS.